Life sciences investor active in late-stage biotech rounds.
Profile being verified
What they look for
Existing investor in Windward Bio since its Series A; participant in Vaderis Therapeutics' Series B, where Francesco Draetta of Omega Funds sits on the board.
Recent investments
Recorded Swiss rounds: Windward Bio (stage not specified, USD 165 M, May 2026), Vaderis Therapeutics (Series B, USD 152 M, August 2026).
Rounds tracked by FundSwiss
- Vaderis TherapeuticsSeries B · USD 152 M
- Windward BioUndisclosed round · USD 165 M